NUTRA PHARMA CORP

$ Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000149315222023751 Filed on August 22, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$0.00	$10.45K	$6.940K
YoY Change	-100.0%	-79.3%	296.57%
Cash & Equivalents		$10.45K
Short-Term Investments
Other Short-Term Assets	$117.7K	$90.65K	$88.40K
YoY Change	-38.71%	13.02%	61.76%
Inventory	$49.35K	$41.65K	$63.84K
Prepaid Expenses	$117.7K	$90.65K
Receivables	$21.58K	$47.31K	$47.00K
Other Receivables	$3.000K		$290.0K
Total Short-Term Assets	$462.5K	$505.0K	$496.2K
YoY Change	-19.17%	38.83%	181.55%
LONG-TERM ASSETS
Property, Plant & Equipment	$85.61K	$91.50K	$172.4K
YoY Change	-44.93%	-48.64%	0.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$99.18K	$101.3K	$107.3K
YoY Change	-7.89%	-5.94%	22.35%
Total Long-Term Assets	$228.2K	$251.7K	$279.7K
YoY Change	-13.28%	-11.94%	8.12%
TOTAL ASSETS
Total Short-Term Assets	$462.5K	$505.0K	$496.2K
Total Long-Term Assets	$228.2K	$251.7K	$279.7K
Total Assets	$690.7K	$756.8K	$775.8K
YoY Change	-17.31%	16.49%	78.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$712.8K	$666.2K	$736.7K
YoY Change	16.47%	23.72%	38.59%
Accrued Expenses	$963.5K	$922.4K	$2.186M
YoY Change	-62.92%	-63.18%	-12.71%
Deferred Revenue	$111.0K
YoY Change
Short-Term Debt	$61.44K	$110.3K	$140.6K
YoY Change	-66.11%	-42.67%	-28.52%
Long-Term Debt Due	$7.863M	$8.260M	$7.017M
YoY Change	1.11%	-2.13%	-17.18%
Total Short-Term Liabilities	$16.15M	$16.74M	$16.19M
YoY Change	-32.08%	-56.77%	-60.89%
LONG-TERM LIABILITIES
Long-Term Debt	$151.7K	$213.9K	$357.7K
YoY Change	-77.03%	-81.04%	-80.49%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$151.7K	$213.9K	$357.7K
YoY Change	-77.71%	-81.68%	-81.1%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.15M	$16.74M	$16.19M
Total Long-Term Liabilities	$151.7K	$213.9K	$357.7K
Total Liabilities	$16.30M	$16.95M	$16.55M
YoY Change	-33.35%	-57.5%	-61.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$76.78M	-$77.36M
YoY Change
Common Stock	$61.16M	$61.15M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$15.61M	-$16.20M	-$15.77M
YoY Change
Total Liabilities & Shareholders Equity	$690.7K	$756.8K	$775.8K
YoY Change	-17.31%	16.49%	78.4%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	91-2021600
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1537 NW 65th Avenue
	dei	Entity Central Index Key EntityCentralIndexKey	0001119643
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent		usd
CY2021Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent		usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	NPHC	Stock Based Loan Modifications StockBasedLoanModifications		usd
CY2021Q2	NPHC	Stock Based Loan Modifications StockBasedLoanModifications		usd
	NPHC	Stock Based Loan Modifications StockBasedLoanModifications		usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount		usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt		usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	NPHC	Warrants Issued With Debtdebt Discount WarrantsIssuedWithDebtdebtDiscount		usd
	NPHC	Increase Of Rightofuse Asset Due To Lease Renewal IncreaseOfRightofuseAssetDueToLeaseRenewal		usd
	NPHC	Increase Of Operating Lease Liabilities Due To Lease Renewa IncreaseOfOperatingLeaseLiabilitiesDueToLeaseRenewa		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q2	NPHC	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes		usd
	NPHC	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes		usd
CY2022Q2	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax		usd
	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax		usd
CY2022Q2	NPHC	Weighted Average Number Of Diluted Shares Convertible Debt WeightedAverageNumberOfDilutedSharesConvertibleDebt		shares
	NPHC	Weighted Average Number Of Diluted Shares Convertible Debt WeightedAverageNumberOfDilutedSharesConvertibleDebt		shares
CY2022Q2	NPHC	Weighted Average Number Of Shares Outstanding Warrants WeightedAverageNumberOfSharesOutstandingWarrants		shares
CY2021Q2	NPHC	Weighted Average Number Of Shares Outstanding Warrants WeightedAverageNumberOfSharesOutstandingWarrants		shares
	NPHC	Weighted Average Number Of Shares Outstanding Warrants WeightedAverageNumberOfSharesOutstandingWarrants		shares
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount		shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount		shares
CY2021Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent		usd
CY2021Q4	us-gaap	Advances Fair Value Disclosure AdvancesFairValueDisclosure		usd
CY2022Q2	us-gaap	Deferred Compensation Equity DeferredCompensationEquity		usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost		usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost		usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-32141
	dei	Entity Registrant Name EntityRegistrantName	NUTRA PHARMA CORP
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	CA
CY2022Q2	us-gaap	Cash Cash	10448	usd
CY2021Q4	us-gaap	Cash Cash	90910	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	47313	usd
CY2022Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	5385988	usd
	dei	Entity Address City Or Town EntityAddressCityOrTown	Plantation
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33313
	dei	City Area Code CityAreaCode	954
	dei	Local Phone Number LocalPhoneNumber	509–0911
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7586352214	shares
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	45998	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	41648	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	31289	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	6000	usd
CY2022Q2	NPHC	Convertible Notes Receivable Current ConvertibleNotesReceivableCurrent	314985	usd
CY2021Q4	NPHC	Convertible Notes Receivable Current ConvertibleNotesReceivableCurrent	273480	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	90650	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	86150	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	505044	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	533827	usd
CY2022Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	92480	usd
CY2021Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	98880	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	91504	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	44701	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	58944	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	93811	usd
CY2022Q2	us-gaap	Security Deposit SecurityDeposit	8803	usd
CY2021Q4	us-gaap	Security Deposit SecurityDeposit	8803	usd
CY2022Q2	us-gaap	Assets Assets	756775	usd
CY2021Q4	us-gaap	Assets Assets	780022	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	666188	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	672372	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	922413	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	851470	usd
CY2022Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1133693	usd
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1053693	usd
CY2022Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	80410	usd
CY2022Q2	us-gaap	Interest Payable Current InterestPayableCurrent	141236	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	147768	usd
CY2022Q2	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	110303	usd
CY2021Q4	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	199726	usd
CY2022Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	147779	usd
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	369401	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	10537344	usd
CY2022Q2	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	8258136	usd
CY2021Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	7598325	usd
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent	2121	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2121	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	39611	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	77673	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	16740099	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21140492	usd
CY2022Q2	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	15076	usd
CY2022Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	51057	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	147779	usd
CY2022Q2	us-gaap	Liabilities Liabilities	16954011	usd
CY2021Q4	us-gaap	Liabilities Liabilities	21657672	usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	12000	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	12000	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	12000000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	12000000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7586352214	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7586352214	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7330985964	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7330985964	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	7586352	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	7330986	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	53565739	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	53508353	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-77361327	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-81728989	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-16197236	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-20877650	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	756775	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	780022	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	90378	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30459	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	112576	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	52482	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	60797	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9006	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	75203	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14640	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	29581	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	21453	usd
	us-gaap	Gross Profit GrossProfit	37373	usd
	us-gaap	Gross Profit GrossProfit	37842	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	10250	usd
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1445	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	20500	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1445	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	348868	usd
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	440165	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	665084	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	944757	usd
CY2022Q2	NPHC	Bad Debt Recovery Related Party BadDebtRecoveryRelatedParty	21799	usd
CY2021Q2	NPHC	Bad Debt Recovery Related Party BadDebtRecoveryRelatedParty	20000	usd
	NPHC	Bad Debt Recovery Related Party BadDebtRecoveryRelatedParty	21799	usd
	NPHC	Bad Debt Recovery Related Party BadDebtRecoveryRelatedParty	73000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	370667	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	460165	usd
	us-gaap	Operating Expenses OperatingExpenses	686883	usd
	us-gaap	Operating Expenses OperatingExpenses	1017757	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-341086	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-438712	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-649510	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-979915	usd
CY2022Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	5500	usd
CY2021Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1715	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	12005	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1715	usd
CY2022Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	195509	usd
CY2021Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	103970	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	384651	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	215310	usd
CY2022Q2	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	4189	usd
CY2021Q2	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	4432	usd
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	8468	usd
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	9377	usd
CY2022Q2	NPHC	Change In Fair Value Of Convertible Notes And Derivatives ChangeInFairValueOfConvertibleNotesAndDerivatives	3484	usd
CY2021Q2	NPHC	Change In Fair Value Of Convertible Notes And Derivatives ChangeInFairValueOfConvertibleNotesAndDerivatives	3918817	usd
	NPHC	Change In Fair Value Of Convertible Notes And Derivatives ChangeInFairValueOfConvertibleNotesAndDerivatives	5549845	usd
	NPHC	Change In Fair Value Of Convertible Notes And Derivatives ChangeInFairValueOfConvertibleNotesAndDerivatives	-28958053	usd
	NPHC	Stock Based Loan Modifications StockBasedLoanModifications	107500	usd
CY2022Q2	NPHC	Loss On Settlement Of Debt And Accrued Expense Net LossOnSettlementOfDebtAndAccruedExpenseNet	114000	usd
CY2021Q2	NPHC	Loss On Settlement Of Debt And Accrued Expense Net LossOnSettlementOfDebtAndAccruedExpenseNet	11200	usd
	NPHC	Loss On Settlement Of Debt And Accrued Expense Net LossOnSettlementOfDebtAndAccruedExpenseNet	151559	usd
	NPHC	Loss On Settlement Of Debt And Accrued Expense Net LossOnSettlementOfDebtAndAccruedExpenseNet	429497	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-304714	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3800930	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5017172	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-29718022	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-645800	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3362218	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4367662	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-30697937	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-645800	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	3362218	usd
	us-gaap	Net Income Loss NetIncomeLoss	4367662	usd
	us-gaap	Net Income Loss NetIncomeLoss	-30697937	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7468989577	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7248545868	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7409580667	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7156417062	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7468989577	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11761879558	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15459963140	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7156417062	shares
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-15773936	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	222500	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-645800	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-16197236	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-42898302	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	33000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	243787	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	15199	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	3362218	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-39244098	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-20877650	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	36000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	276752	usd
	us-gaap	Net Income Loss NetIncomeLoss	4367662	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-16197236	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-11493815	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-11493815	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	33000	usd
	NPHC	Stock Issued During Period Value Debt Modification And Penalty StockIssuedDuringPeriodValueDebtModificationAndPenalty	107500	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2344399	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	462755	usd
	us-gaap	Net Income Loss NetIncomeLoss	-30697937	usd
	us-gaap	Net Income Loss NetIncomeLoss	-30697937	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-39244098	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-39244098	usd
	us-gaap	Net Income Loss NetIncomeLoss	4367662	usd
	us-gaap	Net Income Loss NetIncomeLoss	-30697937	usd
	NPHC	Bad Debts Related Party BadDebtsRelatedParty	21799	usd
	NPHC	Bad Debts Related Party BadDebtsRelatedParty	73000	usd
	NPHC	Accrued Interest Expense For Amount Due To Officer AccruedInterestExpenseForAmountDueToOfficer	2396	usd
	NPHC	Accrued Interest Expense For Amount Due To Officer AccruedInterestExpenseForAmountDueToOfficer	3891	usd
	NPHC	Loss On Settlement Of Debt And Accrued Expense Net LossOnSettlementOfDebtAndAccruedExpenseNet	151559	usd
	NPHC	Loss On Settlement Of Debt And Accrued Expense Net LossOnSettlementOfDebtAndAccruedExpenseNet	429497	usd
	us-gaap	Depreciation Depreciation	11190	usd
	us-gaap	Depreciation Depreciation	3385	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	20500	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1445	usd
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	107500	usd
	NPHC	Amortization Of Convertible Notes Receivable Discount AmortizationOfConvertibleNotesReceivableDiscount	12005	usd
	NPHC	Amortization Of Convertible Notes Receivable Discount AmortizationOfConvertibleNotesReceivableDiscount	1715	usd
	NPHC	Change In Fair Value Of Convertible Notes And Derivatives ChangeInFairValueOfConvertibleNotesAndDerivatives	5549845	usd
	NPHC	Change In Fair Value Of Convertible Notes And Derivatives ChangeInFairValueOfConvertibleNotesAndDerivatives	-28958053	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	267517	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	137881	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	34867	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	11461	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1315	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	807	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	9000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	6000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3959	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	48732	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	25000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	38650	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-6184	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-60960	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	70943	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	18621	usd
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	80000	usd
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	77000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	80410	usd
	NPHC	Increase In Accrued Interest To Related Parties IncreaseInAccruedInterestToRelatedParties	-6532	usd
	NPHC	Increase In Accrued Interest To Related Parties IncreaseInAccruedInterestToRelatedParties	-30623	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-38062	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-34179	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-543059	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1097869	usd
	NPHC	Payments To Convertible Notes Receivable PaymentsToConvertibleNotesReceivable	-14500	usd
	NPHC	Payments To Convertible Notes Receivable PaymentsToConvertibleNotesReceivable	-150500	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	57993	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	30164	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-72493	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-180664	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	35382	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	21900	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	149000	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	107250	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	480000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1492560	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	30507	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	62822	usd
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	251340	usd
	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	52125	usd
	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	15375	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	535090	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1329013	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-80462	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	50480	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	90910	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10448	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	50480	usd
	us-gaap	Interest Paid Net InterestPaidNet	6	usd
	us-gaap	Interest Paid Net InterestPaidNet	40000	usd
	us-gaap	Notes Issued1 NotesIssued1	276752	usd
	us-gaap	Notes Issued1 NotesIssued1	462755	usd
	us-gaap	Stock Issued1 StockIssued1	36000	usd
	us-gaap	Stock Issued1 StockIssued1	2344399	usd
	NPHC	Warrants Issued With Debtdebt Discount WarrantsIssuedWithDebtdebtDiscount	100000	usd
	NPHC	Increase Of Rightofuse Asset Due To Lease Renewal IncreaseOfRightofuseAssetDueToLeaseRenewal	4102	usd
	NPHC	Increase Of Operating Lease Liabilities Due To Lease Renewa IncreaseOfOperatingLeaseLiabilitiesDueToLeaseRenewa	4102	usd
	NPHC	Reclassification Of Other Receivable To Convertible Note Receivable ReclassificationOfOtherReceivableToConvertibleNoteReceivable	15000	usd
	NPHC	Reclassification Of Other Receivable To Convertible Note Receivable ReclassificationOfOtherReceivableToConvertibleNoteReceivable	6000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-77361327	usd
CY2022Q2	NPHC	Working Capital WorkingCapital	-16235055	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-16197236	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_zcb4s0Ocq09a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_ztyQVrzsT5X">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying Unaudited Condensed Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, the recoverability of amounts due from officer, the valuation of stock-based compensation and certain debt and derivative liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	NPHC	Accounting For Shipping And Handling Costs Policy Tex Block AccountingForShippingAndHandlingCostsPolicyTexBlock	<p id="xdx_84C_ecustom--AccountingForShippingAndHandlingCostsPolicyTexBlock_zCWMaRAx2Vl3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zHcxnmDmIgOb">Accounting for Shipping and Handling Costs</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We account for shipping and handling as fulfillment activities and record amounts billed to customers as revenue and the related shipping and handling costs as cost of sales.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8956031220	shares
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	48000	usd
CY2022Q2	us-gaap	Inventory Adjustments InventoryAdjustments	294162	usd
CY2021Q4	us-gaap	Inventory Adjustments InventoryAdjustments	294162	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zhTx4hpjE4ul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zeB8ARE7ulHc">Financial Instruments and Concentration of Credit Risk</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the three months ended June 30, 2022, one customer accounted for <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_z6qgR7XtEDgh">69</span>% of the total revenues. For the three months ended June 30, 2021, one customer accounted for <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zY660Lqk201c">31</span>% of the total revenues. For the six months ended June 30, 2022, one customer accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zqettsp0xYYf">63</span>% of the total revenues. For the six months ended June 30, 2021, one customer accounted for <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zDM6AZkIjVS6">33</span>% of the total revenues. As of June 30, 2022 and December 31, 2021, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zPvLsApIL3S3">97</span>% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zDwmJKT02jUd">100</span>% of the accounts receivable balance are reserves due from two payment processors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>
	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p id="xdx_84A_eus-gaap--DerivativesReportingOfDerivativeActivity_z1JgSfvZ52ri" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zh76eV9zlGW7">Derivative Financial Instruments</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to other income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11761879558	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15459963140	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7156417062	shares
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-645800	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	3362218	usd
	us-gaap	Net Income Loss NetIncomeLoss	4367662	usd
	us-gaap	Net Income Loss NetIncomeLoss	-30697937	usd
CY2021Q2	NPHC	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-1647754	usd
	NPHC	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-732404	usd
CY2021Q2	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	58330	usd
	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	152682	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-645800	usd
CY2021Q2	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	1772794	usd
	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	3787940	usd
	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-30697937	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7468989577	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7248545868	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7409580667	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7156417062	shares
CY2021Q2	NPHC	Weighted Average Number Of Diluted Shares Convertible Debt WeightedAverageNumberOfDilutedSharesConvertibleDebt	4513333690	shares
	NPHC	Weighted Average Number Of Diluted Shares Convertible Debt WeightedAverageNumberOfDilutedSharesConvertibleDebt	7439393188	shares
	NPHC	Weighted Average Number Of Shares Outstanding Warrants WeightedAverageNumberOfSharesOutstandingWarrants	610989285	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7468989577	shares
CY2022Q2	us-gaap	Notes Payable NotesPayable	1336807	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	1135257	usd
CY2022Q2	us-gaap	Depreciation Depreciation	5898	usd
CY2021Q2	us-gaap	Depreciation Depreciation	2012	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4967566386	shares
CY2022Q2	NPHC	Warrant Liability Fair Value Disclosures WarrantLiabilityFairValueDisclosures	376670	usd
CY2022Q2	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	5009318	usd
CY2022Q2	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	2501221	usd
CY2021Q4	NPHC	Warrant Liability Fair Value Disclosures WarrantLiabilityFairValueDisclosures	710585	usd
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	9826759	usd
CY2021Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	2855709	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	710585	usd
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	189543	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases Sales Issuances Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements	100000	usd
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases Sales Issuances Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements	590885	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	433915	usd
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	69843	usd
CY2022Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	376670	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	710585	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	125425	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	126349	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	8703	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3820	usd
CY2022Q2	us-gaap	Inventory Gross InventoryGross	134128	usd
CY2021Q4	us-gaap	Inventory Gross InventoryGross	130169	usd
CY2022Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	92480	usd
CY2021Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	98880	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	41648	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	31289	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	324879	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	266886	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	233375	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	222185	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	91504	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	44701	usd
	us-gaap	Depreciation Depreciation	11190	usd
	us-gaap	Depreciation Depreciation	3385	usd
	NPHC	Bad Debt Recovery Related Party BadDebtRecoveryRelatedParty	21799	usd
	NPHC	Bad Debt Recovery Related Party BadDebtRecoveryRelatedParty	21799	usd
	NPHC	Bad Debt Recovery Related Party BadDebtRecoveryRelatedParty	73000	usd
CY2022Q2	NPHC	Bad Debt Recovery Related Party BadDebtRecoveryRelatedParty	21799	usd
CY2021Q2	NPHC	Bad Debt Recovery Related Party BadDebtRecoveryRelatedParty	20000	usd
CY2022Q2	NPHC	Convertible Notes Payable Unrelated Third Parties ConvertibleNotesPayableUnrelatedThirdParties	4261241	usd
CY2021Q4	NPHC	Convertible Notes Payable Unrelated Third Parties ConvertibleNotesPayableUnrelatedThirdParties	3751760	usd
CY2022Q2	NPHC	Convertible Notes Payable At Fair Value ConvertibleNotesPayableAtFairValue	2501221	usd
CY2021Q4	NPHC	Convertible Notes Payable At Fair Value ConvertibleNotesPayableAtFairValue	2855709	usd
CY2022Q2	NPHC	Other Advances From Unrelated Third Party OtherAdvancesFromUnrelatedThirdParty	225000	usd
CY2021Q4	NPHC	Other Advances From Unrelated Third Party OtherAdvancesFromUnrelatedThirdParty	225000	usd
CY2022Q2	NPHC	Long Term Notes Payables LongTermNotesPayables	149900	usd
CY2021Q4	NPHC	Long Term Notes Payables LongTermNotesPayables	149900	usd
CY2022Q2	us-gaap	Other Notes Payable OtherNotesPayable	8474169	usd
CY2021Q4	us-gaap	Other Notes Payable OtherNotesPayable	8117626	usd
CY2022Q2	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	15076	usd
CY2022Q2	NPHC	Less Longterm Portion Sba Notes Payable LessLongtermPortionSbaNotesPayable	51057	usd
CY2021Q4	NPHC	Less Longterm Portion Sba Notes Payable LessLongtermPortionSbaNotesPayable	369401	usd
CY2022Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	147779	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	147779	usd
CY2022Q2	us-gaap	Debt Current DebtCurrent	8260257	usd
CY2021Q4	us-gaap	Debt Current DebtCurrent	7600446	usd
CY2022Q2	us-gaap	Notes Payable NotesPayable	1336807	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	1135257	usd
CY2022Q2	NPHC	Convertible Notes Payable Unrelated Third Parties ConvertibleNotesPayableUnrelatedThirdParties	4261241	usd
CY2021Q4	NPHC	Convertible Notes Payable Unrelated Third Parties ConvertibleNotesPayableUnrelatedThirdParties	3751760	usd
CY2019Q4	NPHC	Repayments Of Notes Payablerelated Party RepaymentsOfNotesPayablerelatedParty	13500	usd
CY2022Q2	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	2501221	usd
CY2021Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	2855709	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	90650	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	86150	usd
CY2022Q2	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	0	usd
CY2021Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	48000	usd
CY2022Q2	NPHC	Total Valuation Allowance For Prepaid TotalValuationAllowanceForPrepaid	294162	usd
CY2021Q4	NPHC	Total Valuation Allowance For Prepaid TotalValuationAllowanceForPrepaid	294162	usd
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	8000000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	12000000000	shares
CY2020Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	92100000	shares
CY2020Q3	NPHC	Month Of Expiration Of Warrants MonthOfExpirationOfWarrants	August, 2022
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	36300000	shares
CY2020Q4	NPHC	Month Of Expiration Of Warrants MonthOfExpirationOfWarrants	October, 2022
	NPHC	Weighted Average Number Of Shares Outstanding Warrants WeightedAverageNumberOfSharesOutstandingWarrants	610989285	shares
	NPHC	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Non Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableNonOptionsWeightedAverageRemainingContractualTerm2	P0Y5M12D
CY2022Q2	NPHC	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	0.0018
CY2021	NPHC	Weighted Average Number Of Shares Outstanding Warrants WeightedAverageNumberOfSharesOutstandingWarrants	446703571	shares
CY2021	NPHC	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Non Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableNonOptionsWeightedAverageRemainingContractualTerm2	P0Y8M1D
CY2021Q4	NPHC	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	0.0017
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	161550	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	161550	usd
CY2022Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	221662	usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	215543	usd
CY2022Q2	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	536756	usd
CY2021Q4	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	469040	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2445	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5337	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	922413	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	851470	usd
CY2022Q2	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	324162	usd
CY2021Q4	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	294162	usd
CY2022Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	294162	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	294162	usd
CY2022Q2	us-gaap	Advances Fair Value Disclosure AdvancesFairValueDisclosure	30000	usd
CY2022Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	60650	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	65650	usd
CY2021Q4	us-gaap	Deferred Compensation Equity DeferredCompensationEquity	20500	usd
	NPHC	Share Based Compensation Shares Not Yet Issued ShareBasedCompensationSharesNotYetIssued	1500000	shares
CY2021	NPHC	Share Based Compensation Shares Not Yet Issued ShareBasedCompensationSharesNotYetIssued	1500000	shares
	us-gaap	Operating Lease Cost OperatingLeaseCost	40198	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	80396	usd
	us-gaap	Lease Cost LeaseCost	40198	usd
CY2021	us-gaap	Lease Cost LeaseCost	80396	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	58944	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	93811	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	39611	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	77673	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	39611	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	77673	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y6M
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2022Q2	NPHC	Operating Lease Liability Cash Paid For Measurement OperatingLeaseLiabilityCashPaidForMeasurement	43393	usd
CY2021Q4	NPHC	Operating Lease Liability Cash Paid For Measurement OperatingLeaseLiabilityCashPaidForMeasurement	95846	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	40540	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	40540	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	929	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	39611	usd
CY2022Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.18
CY2022Q2	us-gaap	Accrued Liabilities For Commissions Expense And Taxes AccruedLiabilitiesForCommissionsExpenseAndTaxes	142500	usd
CY2016Q4	us-gaap	Deferred Compensation Arrangement With Individual Recorded Liability DeferredCompensationArrangementWithIndividualRecordedLiability	31750	usd
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1000000	shares
CY2022Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	19150	usd
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	19150	usd
	us-gaap	Loss Contingency Allegations LossContingencyAllegations	The violations alleged against the Company by the SEC include: (a) raising over $920,000 in at least two private placement offerings for which the Company failed to file required registration statements with the SEC; (b) issuing a series of materially false or misleading press releases; (c) making false statements in at least one Form 10-Q; and (d) failing to make required public filings with the SEC to disclose the Company’s issuance of millions of shares of stock. The lawsuit makes additional allegations against Mr. McManus and Mr. Deitsch, including that Mr. McManus acted as a broker without SEC registration and defrauded at least one investor by making false statements about the Company, that Mr. Deitsch engaged in manipulative trades of the Company’s stock by offering to pay more for shares he was purchasing than the amount the seller was willing to take, and that Mr. Deitsch failed to make required public filings with the SEC. The lawsuit seeks both injunctive and monetary relief
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd

Files In Submission

Name	View Source	Status
0001493152-22-023751-index-headers.html	Edgar Link	pending
0001493152-22-023751-index.html	Edgar Link	pending
0001493152-22-023751.txt	Edgar Link	pending
0001493152-22-023751-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nphc-20220630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
nphc-20220630_cal.xml	Edgar Link	unprocessable
nphc-20220630_def.xml	Edgar Link	unprocessable
nphc-20220630_lab.xml	Edgar Link	unprocessable
nphc-20220630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

NUTRA PHARMA CORP

2022 Q3 Form 10-Q Financial Statement

#000149315222023751 Filed on August 22, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission